Company intelligence / Profile preview

Tessa Therapeutics

Ownership: Private
Development stage: Phase 2

Overview

The company's lead allogeneic cell therapy, TT11X, demonstrated a 79% overall response rate and 43% complete response rate in heavily pre-treated CD30-positive Hodgkin lymphoma patients in Phase 1 trials. The therapy was well-tolerated with no dose-limiting toxicities or evidence of graft-versus-host-disease. The company's autologous therapy TT11 showed a 57.1% complete response rate in patients with classical Hodgkin's lymphoma in Phase 2 trials[1][9].

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-T therapy
Industry: Biotech

Drug pipeline

10 assets

Rovaleucel

9 more assets in the full pipeline.

Request access →

Partnerships

Baylor College of MedicineU.S. National Cancer InstituteChina-Singapore Guangzhou Knowledge CityParker Institute for Cancer ImmunotherapyVyriad

Beyond the preview

Go deeper on Tessa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tessa Therapeutics.

Explore the full profile